Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, 28 September 2007

Another Look at Asia

Posted on 06:40 by Unknown
As a small follow up to our post last week on Sofinnova Partners' hiring an Asia-focused professional, VentureWire Lifescience reported this week that Canaan Partners added a principal whose partial duties include finding deal flow from Asia.

Mickey Kim will from Canaan's Westport, Conn. office. He joined the firm in July according to his bio.

Mickey joined Canaan from Pacific Point Ventures, a venture capital fund investing in healthcare infrastructure companies in Asia. Prior to co-founding Pacific Point Ventures, he invested in biotech and medical device companies at BioVentures Investors, including ActivBiotics, Applied Spine Technologies, Cylene Pharmaceuticals, Hydra Biosciences and Sciona. Mickey also served as a strategy consultant at McKinsey & Company and CSC Healthcare, and co-founded an Asian technology venture capital fund.

Canaan doesn't appear to have any health care portfolio companies in Asia at this point. It does have two IT-oriented deals in India.

No doubt there will be more news like this to come.
Email ThisBlogThis!Share to XShare to Facebook
Posted in China, India, private equity, venture capital | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • EPO Relabeling: Its Not the Black Box, Its What FDA Says About the Black Box
    Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...
  • While You Were Settling
    Well, it was an interesting weekend: the writers' strike may have been settled, Obama swept (and won a Grammy), and there was an unusual...
  • Payday for RJ Kirk & New River
    Once again, ally turns to buy . Eager to land 100% of the two companies' profits from the soon-to-be-approved ADHD drug Vyvanse (former...
  • At JP Morgan, Stryker's Big Smile
    As he strode to the podium in during last week’s JP Morgan investor conference in San Francisco, Stryker Corp. CEO Steve MacMillan was all s...
  • Cracks in Crucible of Evidence-Based Medicine Create "Climate of Calamity"
    The real story emerging from this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, is not the news per ...
  • The Big Winner in the Vytorin Debacle? It Might be Lilly
    Steve Nissen's latest star turn , advising doctors everywhere to stop using Vytorin until there is better evidence it improves health ou...
  • The Wacky World of Generics: Protonix Edition
    Here is a headscratcher. Wyeth decided January 30 to launch an authorized generic version of its blockbuster proton pump inhibitor pantopraz...
  • Old Medicine in New Bottles
    Two excellent posts from the Wall Street Journal’s Health Blog and Pharmalot noted speculation from Credit Suisse on a Pfizer bid for Wyet...
  • Third Rock's a Charm
    It’s one of the oldest stories out there. Successful management team, a few years removed from running their own successful biopharmaceutica...
  • While You Were Staying Put
    It's always sunny in ... London? Lets kick off the weekend wrap-up by highlighting a trio of stories from The Times about incoming Glax...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ▼  September (33)
      • Co-promotes: No Longer Biotech’s Holy Grail
      • Ortho Settlement Doesn't Settle Everything
      • Another Look at Asia
      • What About Specialty?
      • PSA Day 2: Buying into Biologics
      • Smaller Big Pharma and the Hybrid Future
      • How to Improve Drug Development? Fail Fast!
      • Merck: Embracing Externalization, From the Top Down
      • IPOs: Just Another Facet of the M&A Auction
      • Can't Keep Quiet About This
      • While You Were Packing for New York
      • Strange Bedfellows: Novartis Marries VC & Business...
      • Going, Going.....Google
      • The Right Kind of FDA Defense
      • Shire's Portfolio Solution
      • FDARA: Changing Drug Development in the Guise of S...
      • Sofinnova Partners Talks China
      • The Next Big Thing...
      • Can a Sleep Drug Awaken Demand from European Consu...
      • A New VC On The Block. Finally!
      • While You Were in Italy
      • EPO’s Future Back in FDA’s Hands
      • Third Rock Ready To Roll
      • More Bad News Coming on Avandia
      • Who's Sorry Now? Big Pharma Edition
      • Big Pharma: Beware the Coupon Clippers
      • While You Were Finally Watching Some Football
      • Buyer’s Remorse: No Love for Medicare Part D on th...
      • Why Financiers Like Virtual Companies
      • The Cost of FDA's Credibility Gap
      • EPO Fatigue: Amgen Hopes History Doesn’t Repeat It...
      • Science Matters: A small personalized medicine bai...
      • While You Weren't Working
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile